Role of neuropeptides in migraine: Where do they stand in the latest expert recommendations in migraine treatment?

    Authors

    M. Samsam; R. Covenas; R. Ahangari; J. Yajeya;J. A. Narvaez

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Drug Dev. Res.

    Keywords

    headache; trigeminovascular system; substance P; calcitonin gene-related; peptide; GENE-RELATED PEPTIDE; CAUDAL TRIGEMINAL NUCLEUS; RECEPTOR ANTAGONIST; BIBN4096BS; FAMILIAL HEMIPLEGIC MIGRAINE; FOS-LIKE IMMUNOREACTIVITY; VASOACTIVE INTESTINAL POLYPEPTIDE; NEUROGENIC PLASMA EXTRAVASATION; ENKEPHALIN-LIKE MATERIAL; NOCICEPTIVE DURAL INPUT; SUPERIOR SAGITTAL; SINUS; Chemistry, Medicinal; Pharmacology & Pharmacy

    Abstract

    Many factors have been implicated in the pathogenesis of migraine headache, including activation of the trigeminovascular system, dysfunction of: cerebral blood vessels, circulating vasoactive substances, mitochondrial energy metabolism, brain oxygenation and metabolism, platelet disorder, alterations in serotonin levels, low levels of brain tissue magnesium, altered transport of ions across the cell membrane, and inheritance and dysfunction of the brainstem periaqueductal gray matter. The headache phase of migraine is associated with cerebral vasodilation and inflammation, presumably mediated by the release of vasoactive substances and neuropeptides including CGRP (calcitonin gene-related peptide). Increased serum CGRP levels have been detected during migraine and cluster headache. One strategy to treat migraine is to inhibit the release of neuropeptides or to block their receptors. This article briefly reviews some experimental and clinical investigations focused on neuropeptide involvement in migraine.

    Journal Title

    Drug Development Research

    Volume

    68

    Issue/Number

    6

    Publication Date

    1-1-2007

    Document Type

    Review

    Language

    English

    First Page

    294

    Last Page

    314

    WOS Identifier

    WOS:000252349100005

    ISSN

    0272-4391

    Share

    COinS